Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 12 (December)

1. HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review.
   Gynecol Oncol, 111(3): 568-71. [Abstract] [Full-text]
2. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
   Cancer Chemother Pharmacol, 63(2): 275-80. [Abstract] [Full-text]
3. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.
   Cancer Chemother Pharmacol, 63(2): 219-28. [Abstract] [Full-text]
4. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
   Clin Chem, 54(12): e11-79. [Abstract] [Full-text]
5. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
   J Mammary Gland Biol Neoplasia, 13(4): 485-98. [Abstract] [Full-text]
6. Toxicity of targeted therapies in elderly patients.
   Expert Rev Anticancer Ther, 8(12): 1965-76. [Abstract] [Full-text]
7. Jumping higher: is it still possible? The ALTTO trial challenge.
   Expert Rev Anticancer Ther, 8(12): 1883-90. [Abstract] [Full-text]
8. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
   Expert Rev Anticancer Ther, 8(12): 1859-69. [Abstract] [Full-text]
9. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
   Breast J, 14(6): 562-9. [Abstract] [Full-text]
10. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
    Eur J Nucl Med Mol Imaging, 36(1): 81-93. [Abstract] [Full-text]
11. Her2-positive breast cancer: herceptin and beyond.
    Eur J Cancer, 44(18): 2806-12. [Abstract] [Full-text]
12. Targeted therapies in breast cancer: where are we now?
    Eur J Cancer, 44(18): 2781-90. [Abstract] [Full-text]
13. A pan-HER approach for cancer therapy: background, current status and future development.
    Expert Opin Biol Ther, 9(1): 97-110. [Abstract] [Full-text]
14. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    J Clin Oncol, 26(35): 5697-704. [Abstract] [Full-text]
15. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Breast Cancer, 16(1): 88-92. [Abstract] [Full-text]
16. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Neuro Oncol, 10(6): 946-57. [Abstract] [Full-text]
17. Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
    World J Surg, 33(1): 44-51. [Abstract] [Full-text]
18. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
    Mol Cancer, 7(1): 91. [Abstract] [Full-text]
19. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
    J Natl Cancer Inst, 100(24): 1780-91. [Abstract] [Full-text]
20. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells.
    Int J Cancer, 124(4): 772-7. [Abstract] [Full-text]
21. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Clin Cancer Res, 14(24): 8019-26. [Abstract] [Full-text]
22. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
    Nat Clin Pract Oncol, 6(1): 25-33. [Abstract] [Full-text]
23. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.
    J Clin Oncol, 26(36): 5994-6000. [Abstract] [Full-text]
24. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
    Breast Cancer Res Treat, 113(1): 95-100. [Abstract] [Full-text]
25. Systematic review of HER2 breast cancer testing.
    Appl Immunohistochem Mol Morphol, 17(1): 1-7. [Abstract] [Full-text]
26. Current perspective - trastuzumab.
    Eur J Cancer, 45(1): 12-8. [Abstract] [Full-text]
27. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
    Biomaterials, 30(5): 919-27. [Abstract] [Full-text]
28. Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
    Crit Care Med, 37(1): S22-9. [Abstract] [Full-text]
29. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
    Bioconjug Chem, 19(12): 2321-31. [Abstract] [Full-text]
30. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.
    Oncologist, 13(12): 1224-34. [Abstract] [Full-text]
31. The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer.
    Urol Oncol, 27(1): 53-63. [Abstract] [Full-text]
32. Lessons learned from independent central review.
    Eur J Cancer, 45(2): 268-74. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.